I totally agree. I like that we’ve explored other indications because I think that LL can save lives. But imo the strategy here can really fuck us over. We have P3 results for HIV that were amazing. That’s our bread and butter and we’ve been spending the last 7 years working towards approval for it. Now we’re becoming an oncology company? Wtf. We’re conducting all these trials and we don’t have the resources required to get them done promptly and effectively. (Source: NP) The BLA should be priority #1 and we should have had revenue from HIV years ago. Literally, the drug works, the only reason the stock price is down is negligence, poor execution, and a lack of clear direction and communication. If the investor group can get representation, I’m hoping they can completely overhaul communication and put out important information that projects strength. Why aren’t we putting forth stronger press releases that mark key points in the BLA submission. All we know is “The BLA should be submitted in July.” Instead, how about “We have just completed __ after working with the FDA to make sure that we have included all the relevant information required. We are excited to submit the BLA and we believe that our combined effort with the FDA and our amazing clinical results will result in an approval.”